EUVIMEDEUVIMED entdecken
Crossref

Enhancing bioavailability of a weakly basic drug through cocrystallization: PBPK modeling of ketoconazole–succinic acid

Ana Karolina Santos Goes, Amira Soliman, Venkata Krishna Kowthavarapu, Paulo Renato Oliveira, Natalia Valadares de Moraes

European Journal of Pharmaceutics and Biopharmaceutics · 2026

DOI: 10.1016/j.ejpb.2026.114986 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026. Verfasst von Ana Karolina Santos Goes und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, 6550 Sanger Road, Orlando, FL 32827, USA; De…. Hauptthemen laut MEDLINE: Ketoconazole, Succinic Acid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Coordination for the improvement of Higher Education Personnel, CNPq.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmaceutical cocrystals, formed by combining an active pharmaceutical ingredient (API) with a suitable coformer, offer a promising strategy to enhance drug solubility, stability, and dissolution, thereby improving absorption and bioavailability without altering pharmacological properties. This approach is particularly advantageous for poorly soluble drugs such as ketoconazole (KTZ), a BCS Class II compound characterized by dissolution-limited absorption and variable oral bioavailability. As a weak dibasic drug, KTZ exhibits pH-dependent dissolution, which was favored under acidic gastric conditions. To overcome the pH-dependent dissolution, a cocrystal of KTZ with succinic acid (SA) was developed and a physiologically based pharmacokinetic (PBPK) approach informed by in vitro solubility and dissolution data was used to predict KTZ plasma concentration profiles, following administration of KTZ or KTZ-SA cocrystal. The developed PBPK model was verified, with a predicted/observed AUC ratio within a 2-fold range for KTZ. The model successfully captured the reduced exposure to KTZ when administered with omeprazole. PBPK simulations demonstrated a reduced KTZ exposure following a 200 mg dose under achlorhydric conditions (AUC: 1.1 µg·h·mL-1) or with omeprazole administration (AUC: 3.1 µg·h·mL-1), compared to healthy subjects (AUC: 12.2 µg·h·mL-1). In contrast, KTZ-SA cocrystal achieved consistently similar exposure in healthy subjects (AUC: 17.2 µg·h·mL-1), achlorhydric populations (AUC: 18.6 µg·h·mL-1), or when coadministered with omeprazole (AUC: 16.9 µg·h·mL-1). This model-based approach has demonstrated the potential of KTZ-SA cocrystal to enhance bioavailability in populations with achlorhydria-related disparities, effectively addressing the challenges posed by variable gastric acidity. The findings support the development of pharmaceutical cocrystals to optimize drug delivery and maximize therapeutic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetoconazoleSuccinic AcidBiological AvailabilityHumansCrystallizationSolubilityBulk DrugsModels, BiologicalHydrogen-Ion ConcentrationAdministration, OralMaleArea Under CurveOmeprazoleAdult

Stichwörter der Autor:innen

BioavailabilityCocrystalCocrystalizationKetoconazolePBPK

Substanzen

KetoconazoleBulk DrugsSuccinic AcidOmeprazole

Autor:innen und Institutionen

  • Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, 6550 Sanger Road, Orlando, FL 32827, USA; Department of Pharmacy, Universidade Estadual do Centro-Oeste (UNICENTRO…
  • Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, 6550 Sanger Road, Orlando, FL 32827, USA; Department of Pharmacy Practice, Faculty of Pharmacy, Helwan University,…
  • Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, 6550 Sanger Road, Orlando, FL 32827, USA.
  • Department of Pharmacy, Universidade Estadual do Centro-Oeste (UNICENTRO), Alameda Élio Antonio Dalla Vecchi 838, Guarapuava, PR 85040-167, Brazil.
  • Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, 6550 Sanger Road, Orlando, FL 32827, USA. Electronic address: nataliademoraes@ufl.edu.

Förderung

  • Coordination for the improvement of Higher Education Personnel
  • CNPq

Zitieren

APA

Santos Goes, A. K., Soliman, A., Kowthavarapu, V. K., Oliveira, P. R., & de Moraes, N. V. (2026). Enhancing bioavailability of a weakly basic drug through cocrystallization: PBPK modeling of ketoconazole–succinic acid. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2026.114986

Vancouver

Santos Goes AK, Soliman A, Kowthavarapu VK, Oliveira PR, de Moraes NV. Enhancing bioavailability of a weakly basic drug through cocrystallization: PBPK modeling of ketoconazole–succinic acid. European Journal of Pharmaceutics and Biopharmaceutics. 2026. doi:10.1016/j.ejpb.2026.114986

BibTeX
@article{SantosGoes2026,
  author = {Santos Goes, Ana Karolina and Soliman, Amira and Kowthavarapu, Venkata Krishna and Oliveira, Paulo Renato and de Moraes, Natalia Valadares},
  title = {Enhancing bioavailability of a weakly basic drug through cocrystallization: PBPK modeling of ketoconazole–succinic acid},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2026},
  doi = {10.1016/j.ejpb.2026.114986}
}
Kostenlos starten →